Article Details
Retrieved on: 2023-01-13 15:04:14
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The 466-page FDA submission on the preclinical program discussed by Latypova is in fact Pfizer's submission on BioNTech's behalf. As detailed in The ...
Article found on: brownstone.org
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here